No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CARM Carisma Therapeutics
- 1.630
- -0.080-4.68%
Close Apr 19 16:00 ET
- 1.630
- 0.0000.00%
Post 19:10 ET
67.71MMarket Cap-762P/E (TTM)
1.730High1.530Low257.38KVolume1.700Open1.710Pre Close413.48KTurnover1.14%Turnover RatioLossP/E (Static)41.54MShares9.76652wk High2.55P/B36.68MFloat Cap1.53052wk Low--Dividend TTM22.51MShs Float51.357Historical High--Div YieldTTM11.70%Amplitude1.530Historical Low1.606Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Buy Rating Affirmed: Promising Clinical Data and Strategic Shift Bolster Carisma Therapeutics' Outlook
Promising Future for Carisma Therapeutics' Cancer Immunotherapy: A Buy Rating Analysis
CARISMA Therapeutics Price Target Announced at $6.00/Share by BTIG
CARISMA Therapeutics Price Target Announced at $6.00/Share by BTIG
BTIG Sees Carisma Therapeutics as 'Undervalued', Starts Shares Coverage With Buy
Express News | Carisma Therapeutics Inc : Btig Initiates Coverage With Buy Rating ; Target Price $6
Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), Avidity Biosciences (RNA) and Vera Therapeutics (VERA)
Comments
$Carisma Therapeutics(CARM.US$ is this a good stock?
Carisma Therapeutics' low P/S ratio may be due to limited future growth expectations. Its underwhelming revenue outlook contributes to this low P/S, making a significant share price rise unlikely soon.
News
$Carisma Therapeutics(CARM.US$ Carisma Therapeutics Has Nominated Its First Lead Candidate Under The Collaboration With Moderna That Will Target An Antigen Present On A Solid Tumor
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg